These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 30883509)

  • 1. Pharmacodynamic Monitoring of mTOR Inhibitors.
    Millán O; Wieland E; Marquet P; Brunet M
    Ther Drug Monit; 2019 Apr; 41(2):160-167. PubMed ID: 30883509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic monitoring of mammalian target of rapamycin inhibition by phosphoflow cytometric determination of p70S6 kinase activity.
    Hoerning A; Wilde B; Wang J; Tebbe B; Jing L; Wang X; Jian F; Zhu J; Dolff S; Kribben A; Hoyer PF; Witzke O
    Transplantation; 2015 Jan; 99(1):210-9. PubMed ID: 25099702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assay validation of phosphorylated S6 ribosomal protein for a pharmacodynamic monitoring of mTOR-inhibitors in peripheral human blood.
    Dieterlen MT; Bittner HB; Klein S; von Salisch S; Mittag A; Tárnok A; Dhein S; Mohr FW; Barten MJ
    Cytometry B Clin Cytom; 2012 May; 82(3):151-7. PubMed ID: 22213594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of a phosphoflow assay to determine phosphorylation of S6 ribosomal protein as a pharmacodynamic read out for mTOR inhibition.
    Abdel-Kahaar E; Kabakchiev M; Hartmann B; Wieland E; Shipkova M
    Clin Biochem; 2016 Oct; 49(15):1181-1187. PubMed ID: 27372285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes.
    Shihab F; Christians U; Smith L; Wellen JR; Kaplan B
    Transpl Immunol; 2014 Jun; 31(1):22-32. PubMed ID: 24861504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Target Enzyme Activity and Phosphorylation of Pathway Molecules As Specific Biomarkers in Transplantation.
    Budde K; Sommerer C; Rissling O; Dieterlen MT; Barten MJ
    Ther Drug Monit; 2016 Apr; 38 Suppl 1():S43-9. PubMed ID: 26977999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with mTOR inhibitors after liver transplantation enables a sustained increase in regulatory T-cells while preserving their suppressive capacity.
    Ghazal K; Stenard F; Dahlqvist G; Barjon C; Aoudjehane L; Scatton O; Conti F
    Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):237-244. PubMed ID: 29175009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mTOR Inhibition and Clinical Transplantation: Kidney.
    Flechner SM
    Transplantation; 2018 Feb; 102(2S Suppl 1):S17-S18. PubMed ID: 28230636
    [No Abstract]   [Full Text] [Related]  

  • 9. mTOR Inhibition and Clinical Transplantation: Heart.
    Zuckermann A; Osorio-Jaramillo E; Aliabadi-Zuckermann AZ
    Transplantation; 2018 Feb; 102(2S Suppl 1):S27-S29. PubMed ID: 29369971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of mTOR Inhibitors in the Management of Viral Infections: A Review of Current Literature.
    Bowman LJ; Brueckner AJ; Doligalski CT
    Transplantation; 2018 Feb; 102(2S Suppl 1):S50-S59. PubMed ID: 29369973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Long Journey of mTOR Inhibitors and the Long Path That Is Still Ahead.
    Tedesco Silva H
    Transplantation; 2018 Feb; 102(2S Suppl 1):S1-S2. PubMed ID: 29369969
    [No Abstract]   [Full Text] [Related]  

  • 12. mTOR Inhibition and Clinical Transplantation: Pancreas and Islet.
    Berney T; Andres A; Toso C; Majno P; Squifflet JP
    Transplantation; 2018 Feb; 102(2S Suppl 1):S30-S31. PubMed ID: 28230643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sirolimus and Everolimus Pathway: Reviewing Candidate Genes Influencing Their Intracellular Effects.
    Granata S; Dalla Gassa A; Carraro A; Brunelli M; Stallone G; Lupo A; Zaza G
    Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27187382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions.
    Fernandes-Silva G; Ivani de Paula M; Rangel ÉB
    Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):367-385. PubMed ID: 27659512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mTOR Inhibition and Kidney Diseases.
    Ma MKM; Yung S; Chan TM
    Transplantation; 2018 Feb; 102(2S Suppl 1):S32-S40. PubMed ID: 29369972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sirolimus and everolimus in kidney transplantation.
    Moes DJ; Guchelaar HJ; de Fijter JW
    Drug Discov Today; 2015 Oct; 20(10):1243-9. PubMed ID: 26050578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. mTOR treatment in lymphangioleiomyomatosis: the role of everolimus.
    Yates DH
    Expert Rev Respir Med; 2016; 10(3):249-60. PubMed ID: 26847859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mTOR Inhibition and Clinical Transplantation: Liver.
    Nashan B
    Transplantation; 2018 Feb; 102(2S Suppl 1):S19-S26. PubMed ID: 28230639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus and sirolimus in transplantation-related but different.
    Klawitter J; Nashan B; Christians U
    Expert Opin Drug Saf; 2015 Jul; 14(7):1055-70. PubMed ID: 25912929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug interaction between cyclosporine and mTOR inhibitors in experimental model of chronic cyclosporine nephrotoxicity and pancreatic islet dysfunction.
    Piao SG; Bae SK; Lim SW; Song JH; Chung BH; Choi BS; Yang CW
    Transplantation; 2012 Feb; 93(4):383-9. PubMed ID: 22267156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.